Thymosin Beta 4 (TB500) (20mg)
ā¢ Composition and format
Thymosin Beta 4 (TB500) (20 mg) is a research-grade peptide supplied as a 20 mg lyophilized powder in a single vial. The batch-specific Certificate of Analysis (COA) provides sequence confirmation, net peptide content, and formulation details to support method-level reproducibility and documentation control.
ā¢ Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use.
ā¢ Intended research use
TB500 is evaluated in controlled in-vitro systems interrogating actin-binding dynamics, cellular migration, extracellular matrix organization, and angiogenic pathway signaling. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes.
ā¢Ā Research characteristics and applications
This research peptide interacts with actin-binding domains and influences cytoskeletal organization and angiogenic pathway signaling. It is utilized in in-vitro systems designed to study cellular migration, tissue matrix modeling, and the regulation of soft-tissue structural components. Its activity profile provides a foundation for research focused on cell motility, vascular formation, and extracellular matrix coordination.
ā¢ Manufacturing and documentation
Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness.
Research Use Only (RUO) Statement
ā¢ For in-vitro research only
ā¢ Not for human or animal consumption
ā¢ Not for diagnostic or therapeutic use
Original: $105.00
-70%$105.00
$31.50Thymosin Beta 4 (TB500) (20mg)
ā¢ Composition and format
Thymosin Beta 4 (TB500) (20 mg) is a research-grade peptide supplied as a 20 mg lyophilized powder in a single vial. The batch-specific Certificate of Analysis (COA) provides sequence confirmation, net peptide content, and formulation details to support method-level reproducibility and documentation control.
ā¢ Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use.
ā¢ Intended research use
TB500 is evaluated in controlled in-vitro systems interrogating actin-binding dynamics, cellular migration, extracellular matrix organization, and angiogenic pathway signaling. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes.
ā¢Ā Research characteristics and applications
This research peptide interacts with actin-binding domains and influences cytoskeletal organization and angiogenic pathway signaling. It is utilized in in-vitro systems designed to study cellular migration, tissue matrix modeling, and the regulation of soft-tissue structural components. Its activity profile provides a foundation for research focused on cell motility, vascular formation, and extracellular matrix coordination.
ā¢ Manufacturing and documentation
Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness.
Research Use Only (RUO) Statement
ā¢ For in-vitro research only
ā¢ Not for human or animal consumption
ā¢ Not for diagnostic or therapeutic use
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
ā¢ Composition and format
Thymosin Beta 4 (TB500) (20 mg) is a research-grade peptide supplied as a 20 mg lyophilized powder in a single vial. The batch-specific Certificate of Analysis (COA) provides sequence confirmation, net peptide content, and formulation details to support method-level reproducibility and documentation control.
ā¢ Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use.
ā¢ Intended research use
TB500 is evaluated in controlled in-vitro systems interrogating actin-binding dynamics, cellular migration, extracellular matrix organization, and angiogenic pathway signaling. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes.
ā¢Ā Research characteristics and applications
This research peptide interacts with actin-binding domains and influences cytoskeletal organization and angiogenic pathway signaling. It is utilized in in-vitro systems designed to study cellular migration, tissue matrix modeling, and the regulation of soft-tissue structural components. Its activity profile provides a foundation for research focused on cell motility, vascular formation, and extracellular matrix coordination.
ā¢ Manufacturing and documentation
Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness.
Research Use Only (RUO) Statement
ā¢ For in-vitro research only
ā¢ Not for human or animal consumption
ā¢ Not for diagnostic or therapeutic use
